Abstract:He has worked within the field of substance use for 30 years initially as a Nurse at The Maryland Centre working with people who inject drugs, before moving into academia and building an international reputation within the field of human enhancement drugs, in particular, the use of anabolic steroids and associated drugs. In 2019 he co-edited the Routledge book Human Enhancement Drugs and in 2020, he founded the Anabolic Steroid United Kingdom Network and leads the National Institute for Health Research (NIHR) … Show more
“…In the United Kingdom, AAS users seek non-judgemental service environments like “steroid clinics” due to their understanding of AAS use, and these clinics, offering more interventions, might better maintain contact with users compared to needle exchange programmes, where AAS users have fewer visits (Kimergard & McVeigh, 2014b). The criminalisation of AAS use significantly magnifies these challenges, even in countries where personal AAS use is legal, stigma and fear remain prominent concerns (McVeigh & Bates, 2022; McVeigh et al, 2022). Our data suggest that if personal AAS possession were legalised, stigma-related barriers might lessen, although the nuances of stigma and other challenges could still persist.…”
Section: Discussionmentioning
confidence: 99%
“…The growing recognition of AAS consumption as a hazardous form of substance use (Goldman et al, 2019; McVeigh et al, 2022; Sagoe et al, 2015) has led to the emergence of discursive frameworks aimed at investigating and addressing this emerging public health concern. Of these frameworks, this study utilises a psycho-criminological framework and its construction of the AAS user as a rational drug consumer.…”
This study aimed to investigate how Anabolic–Androgenic Steroid (AAS) users and healthcare professionals perceive the criminalisation of AAS on users’ ability to seek help and, ultimately, what effect this has on the health outcomes for these consumers. This study triangulated the views ( N = 24) of male ( n = 8) and female ( n = 7) AAS users ( Mage = 35.4, SD = 9.1), as well as healthcare providers ( n = 9), regarding how the criminalisation of AAS had an impact on consumers’ health behaviours and help-seeking. Data were analysed thematically. An overarching narrative was developed regarding the “politicogenic drug effects” which emerge from the illegality of AAS with three overarching themes. First, participants expressed challenges in seeking help and support due to the stigma and fear associated with the illegal nature of AAS use. This fear stemmed from the criminalisation of AAS and the potential legal consequences. Participants also highlighted the social challenges and the need for secrecy surrounding AAS use, which further hindered open discussions and engagement with healthcare providers. The cohort emphasised the close-knit social networks among AAS users, offering support and shared experiences but also entangled in the criminality associated with AAS use. Moreover, participants acknowledged the difficulties in promoting harm reduction initiatives due to the need for secrecy and the potential social and economic disadvantages. The escalation of AAS criminalisation that has impacted both consumers and healthcare professionals has exacerbated the challenges associated with their interaction, further impeding a relationship already fraught with obstacles. Consequently, users remain entrenched within the illicit market, with few options for harm reduction intervention. The study advocates for a rethinking of AAS policies, considering a potential reclassification aligned with the United Kingdom's Class C framework to destigmatise use and promote harm reduction. This shift would require comprehensive research to assess its impact on public health, user behaviour, and harm reduction outcomes.
“…In the United Kingdom, AAS users seek non-judgemental service environments like “steroid clinics” due to their understanding of AAS use, and these clinics, offering more interventions, might better maintain contact with users compared to needle exchange programmes, where AAS users have fewer visits (Kimergard & McVeigh, 2014b). The criminalisation of AAS use significantly magnifies these challenges, even in countries where personal AAS use is legal, stigma and fear remain prominent concerns (McVeigh & Bates, 2022; McVeigh et al, 2022). Our data suggest that if personal AAS possession were legalised, stigma-related barriers might lessen, although the nuances of stigma and other challenges could still persist.…”
Section: Discussionmentioning
confidence: 99%
“…The growing recognition of AAS consumption as a hazardous form of substance use (Goldman et al, 2019; McVeigh et al, 2022; Sagoe et al, 2015) has led to the emergence of discursive frameworks aimed at investigating and addressing this emerging public health concern. Of these frameworks, this study utilises a psycho-criminological framework and its construction of the AAS user as a rational drug consumer.…”
This study aimed to investigate how Anabolic–Androgenic Steroid (AAS) users and healthcare professionals perceive the criminalisation of AAS on users’ ability to seek help and, ultimately, what effect this has on the health outcomes for these consumers. This study triangulated the views ( N = 24) of male ( n = 8) and female ( n = 7) AAS users ( Mage = 35.4, SD = 9.1), as well as healthcare providers ( n = 9), regarding how the criminalisation of AAS had an impact on consumers’ health behaviours and help-seeking. Data were analysed thematically. An overarching narrative was developed regarding the “politicogenic drug effects” which emerge from the illegality of AAS with three overarching themes. First, participants expressed challenges in seeking help and support due to the stigma and fear associated with the illegal nature of AAS use. This fear stemmed from the criminalisation of AAS and the potential legal consequences. Participants also highlighted the social challenges and the need for secrecy surrounding AAS use, which further hindered open discussions and engagement with healthcare providers. The cohort emphasised the close-knit social networks among AAS users, offering support and shared experiences but also entangled in the criminality associated with AAS use. Moreover, participants acknowledged the difficulties in promoting harm reduction initiatives due to the need for secrecy and the potential social and economic disadvantages. The escalation of AAS criminalisation that has impacted both consumers and healthcare professionals has exacerbated the challenges associated with their interaction, further impeding a relationship already fraught with obstacles. Consequently, users remain entrenched within the illicit market, with few options for harm reduction intervention. The study advocates for a rethinking of AAS policies, considering a potential reclassification aligned with the United Kingdom's Class C framework to destigmatise use and promote harm reduction. This shift would require comprehensive research to assess its impact on public health, user behaviour, and harm reduction outcomes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.